Effects of pemafibrate in CKD Patients with hypertriglyceridemia

JRCT ID: jRCT1041240077

Registered date:28/08/2024

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Chronic kidney disease patients with hypertriglyceridemia
• Date of first enrollment: 28/08/2024
• Target sample size: 30
• Study type: Observational

Outcome(s)

• Primary Outcome: Percentage of TG concentrations achieving less than 150 mg/dL during the evaluation period

Secondary Outcome

Secondary endpoints serum creatinine, urinalysis (FABP, urine NAG, urine b2-microglobulin, urine protein), etc.
Cardiac markers BNP, NT pro BNP
Renal markers serum creatinine, urinalysis (FABP, urine NAG, urine b2-microglobulin, urine protein)
Exploratory markers TNF-a, IL-6, hsCRP

Key inclusion & exclusion criteria

• Age minimum: >= 16age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

(i) Serum TG greater than 150 mg/dL
(ii) eGFR less than 20 mL/min/1.73 m2

Exclude criteria

(i) Patients with any of the following
Patients with malignant tumors
Patients on immunosuppressive drugs
(ii) Other research subjects who are judged by the principal investigator or physician in charge to be unsuitable for the safe conduct of this study.

Related Information

• Primary Sponsor: MIMA AKIRA